Richard Curnock, Nigel D. Heaton, Hector Vilca‐Melendez, Anil Dhawan, Nedim Hadzic, Roshni Vara – 12 November 2019 – Liver transplantation (LT) for patients with propionic acidemia (PA) is an emerging therapeutic option. We present a retrospective review of patients with PA who underwent LT at a tertiary liver center between 1995 and 2015. A total of 14 children were identified (8 males) with median age at initial presentation of 3 days (range, 0‐77 days).

Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, Fabien Zoulim, the 2019 EASL‐AASLD HBV Treatment Endpoints Conference Faculty – 12 November 2019 – Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to “cure” HBV. Agreement among the conference participants was reached on some key points.

Po‐Hsun Huang, Chien‐Chang Liao, Meng‐Hsiang Chen, Tung‐Liang Huang, Chao‐Long Chen, Hsin‐You Ou, Yu‐Fan Cheng – 12 November 2019 – Image evaluation of the vascular architecture is essential before living donor liver transplantation (LDLT). However, the use of contrast‐enhanced study in recipients with impaired renal function is limited due to the risk of acute kidney injury and nephrogenic systemic fibrosis. Therefore, a contrast medium–free method is both valuable and necessary for preoperative vascular evaluation.

Harriet Gaskell, Xiaodong Ge, Romain Desert, Sukanta Das, Hui Han, Daniel Lantvit, Grace Guzman, Natalia Nieto – 12 November 2019 – Nonalcoholic steatohepatitis (NASH) is a metabolic disorder in which poor nutrition and the gut‐to‐liver interaction play a major role. We previously established that hepatic high mobility group box‐1 (HMGB1) is involved in chronic liver disease. HMGB1 increases in patients with NASH and it is expressed in intestinal epithelial cells (IEC); yet, the role of intestinal HMGB1 in the pathogenesis of NASH has not been investigated.

Giuseppe Cullaro, Rajani Sharma, Jonel Trebicka, Andrés Cárdenas, Elizabeth C. Verna – 12 November 2019 – Acute‐on‐chronic liver failure (ACLF) is a feared complication that can develop at any stage of chronic liver disease. The incidence of ACLF is increasing, leading to a significant burden to both the affected individual and health care systems. To date, our understanding of ACLF suggests that it may be initiated by precipitants such as systemic infection, alcohol use, or viral hepatitis.

Kerstin Schneeberger, Natalia Sánchez‐Romero, Shicheng Ye, Frank G. Steenbeek, Loes A. Oosterhoff, Iris Pla Palacin, Chen Chen, Monique E. Wolferen, Gilles Tienderen, Ruby Lieshout, Haaike Colemonts‐Vroninks, Imre Schene, Ruurdtje Hoekstra, Monique M.A. Verstegen, Luc J.W. Laan, Louis C. Penning, Sabine A. Fuchs, Hans Clevers, Joery De Kock, Pedro M. Baptista, Bart Spee – 12 November 2019

AASLD members at all career stages are increasingly involved in social media like Twitter. This timely, lively discussion will explore the risks and benefits of tweeting from the perspectives of trainees, researchers, division leaders and journal editors.

AASLD Guideline/Guidance Statements on treating hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and alcohol-related liver disease (ALD) are now updated to reflect data published since 2010, when the previous versions were released. At this session, the guidelines’ authors will highlight important changes hepatologists should know and discuss controversial or challenging issues in treating patients with these chronic liver diseases.

Discover how allocation impacts long-term outcomes for the transplant recipient and liver graft at this session. Speakers will address ways to improve the ability to interpret and identify the significance of long-term, post-transplant liver biopsy findings and offer tools to expand one’s perspective on individualizing immunosuppression to optimize long-term outcomes for the allograft and recipient.

Don’t overlook any of the groundbreaking basic science research presented at The Liver Meeting®. New this year, an expert will briefly review all the basic science abstracts presented at the meeting in one condensed session.